Will secukinumab affect fertility?

Secukinumab is a fully human monoclonal antibody that has shown sustained efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis and has a good safety profile. It can theoretically cross the placenta, but most antibody transfer occurs in the third trimester of pregnancy. Animal studies have not shown adverse effects of secukinumab on pregnancy, embryonic or fetal development, delivery, or postnatal development, including immune morphology and responses. The effects of secukinumab on pregnancy outcomes or spermatogenesis have not been studied in clinical trials, and patients must discontinue study drug if they become pregnant.